KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Debt (2016 - 2025)

Ionis Pharmaceuticals has reported Total Debt over the past 17 years, most recently at $460.1 million for Q4 2025.

  • Quarterly results put Total Debt at $460.1 million for Q4 2025, up 786.04% from a year ago — trailing twelve months through Dec 2025 was $460.1 million (up 786.04% YoY), and the annual figure for FY2025 was $460.1 million, up 786.04%.
  • Total Debt for Q4 2025 was $460.1 million at Ionis Pharmaceuticals, down from $630.9 million in the prior quarter.
  • Over the last five years, Total Debt for IONS hit a ceiling of $630.9 million in Q3 2025 and a floor of $8.8 million in Q1 2023.
  • Median Total Debt over the past 5 years was $51.9 million (2024), compared with a mean of $142.3 million.
  • Biggest five-year swings in Total Debt: plummeted 75.44% in 2022 and later skyrocketed 1318.83% in 2025.
  • Ionis Pharmaceuticals' Total Debt stood at $63.2 million in 2021, then plummeted by 74.74% to $16.0 million in 2022, then skyrocketed by 439.46% to $86.2 million in 2023, then plummeted by 39.74% to $51.9 million in 2024, then surged by 786.04% to $460.1 million in 2025.
  • The last three reported values for Total Debt were $460.1 million (Q4 2025), $630.9 million (Q3 2025), and $630.1 million (Q2 2025) per Business Quant data.